TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39386444

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy with letrozole
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of mitochondrial complex I
Number of subjects: 32

Group type: COMPARATOR
Intervention: Endocrine therapy (letrozole)
Number of subjects: 32
Study: 39387110

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Intravenous alteplase
Number of subjects: 480
Study: 39387205

Group type: EXPERIMENTAL
Intervention: Personalised optimised diet (PD) incorporating two plant protein fibre (PPF) products
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) programme
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Personalised optimised diet (PD) + Physical activity (PA) programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 180
Study: 39387211

Group type: EXPERIMENTAL
Intervention: WEAR + conventional rehabilitation (WG)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CG)
Number of subjects: 127
Study: 39387227

Group type: EXPERIMENTAL
Intervention: Intervention (not specified in detail)
Number of subjects: 0
Study: 39387403

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other disease-modifying antirheumatic drugs
Number of subjects: 0
Study: 39387441

Group type: EXPERIMENTAL
Intervention: Asciminib (oral), dose-escalation in second-line treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asciminib (oral), dose-escalation in first-line treatment
Number of subjects: 0
Study: 39387766

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 12097

Group type: COMPARATOR
Intervention: Renin-angiotensin system inhibitor (RASi)
Number of subjects: 12097
Study: 39387771

Group type: EXPERIMENTAL
Intervention: BMAD-TX (intervention arm using HFMS data)
Number of subjects: 522

Group type: COMPARATOR
Intervention: BMAD-HF (control arm without HFMS data)
Number of subjects: 522
Study: 39387783

Group type: EXPERIMENTAL
Intervention: Hostile score
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Prostar
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: MANTA
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2023

Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic curves
Number of subjects: 2023
Study: 39387937

Group type: EXPERIMENTAL
Intervention: External electrical cardioversion (EC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atrioventricular node ablation
Number of subjects: 43
Study: 39387999

Group type: EXPERIMENTAL
Intervention: CBO-based implementation of Keep It Up!
Number of subjects: 62
Study: 39388024

Group type: EXPERIMENTAL
Intervention: VenKd (venetoclax + carfilzomib + dexamethasone)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Kd (carfilzomib + dexamethasone)
Number of subjects: 57
Study: 39388061

Group type: EXPERIMENTAL
Intervention: Photoplethysmography-based wristband (CardioWatch 287-2, Corsano Health)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nellcor fingerclip and 5-lead ECG (QMAPP Haemodynamic Monitoring module, Fysicon B.V.)
Number of subjects: 100
Study: 39388183

Group type: EXPERIMENTAL
Intervention: EMAF plus PF plus PPC (most intensive strategy)
Number of subjects: 8978

Group type: COMPARATOR
Intervention: EMAF (least intensive strategy)
Number of subjects: 8978
Study: 39388196

Group type: EXPERIMENTAL
Intervention: Transoral Laser Microsurgery (TLM)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS)
Number of subjects: 508
Study: 39388228

Group type: EXPERIMENTAL
Intervention: P3 DHI (couples-based, digital HIV serostatus-neutral intervention) for 6 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Delayed control condition (access to P3 DHI for last 3 months)
Number of subjects: 74
Study: 39388231

Group type: EXPERIMENTAL
Intervention: Multimodal health services intervention (technology-enabled, telehealth-delivered, 4-level intervention)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Multimodal health services intervention
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study: 39388670

Group type: EXPERIMENTAL
Intervention: Communities That HEAL Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-List Control
Number of subjects: 0
Study: 39388688

Group type: EXPERIMENTAL
Intervention: mHealth intervention (mobile health app)
Number of subjects: 98
Study: 39388851

Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 109
Study: 39388898

Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 109
Study: 39389055

Group type: EXPERIMENTAL
Intervention: Zorifertinib
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (first-generation EGFR-TKI: gefitinib or erlotinib)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (first-generation EGFR-TKI)
Number of subjects: 439
Study: 39389071

Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam
Number of subjects: 422

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam (for complicated intra-abdominal infection)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Meropenem (for complicated intra-abdominal infection)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam (for HAP-VAP)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Meropenem (for HAP-VAP)
Number of subjects: 422
Study: 39389076

Group type: EXPERIMENTAL
Intervention: MVA-MERS-S vaccine (10^8 PFU) administered intramuscularly in three doses at 28-day intervals
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Second vaccination with MVA-MERS-S (10^8 PFU)
Number of subjects: 140
Study: 39389081

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks (cohort 1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 3)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 4)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 5)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 6)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study: 39389294

Group type: EXPERIMENTAL
Intervention: Tour of the NIH Clinical Center with unique events at ten specific locations; memory tested after 1 hour and fifteen months.
Number of subjects: 1

Group type: COMPARATOR
Intervention: Subsequent recognition memory tests using novel picture stimuli in a standard laboratory-style computer task.
Number of subjects: 1
Study: 39389429

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 379

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 379

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 379
Study: 39389587

Group type: EXPERIMENTAL
Intervention: Lateral Quadratus Lumborum Block (QLB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Pericapsular Nerve Group Block (PENG) + Lateral Femoral Cutaneous Nerve Block (LFC)
Number of subjects: 101
Study: 39389596

Group type: EXPERIMENTAL
Intervention: Paradoxical intention (PI)
Number of subjects: 40
Study: 39389598

Group type: EXPERIMENTAL
Intervention: Dynamic LED lighting scenario (higher daytime and lower evening-time melanopic daylight equivalent illuminance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lighting scenario (dynamic colour temperature and fixed light intensity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic LED lighting scenario
Number of subjects: 0
Study: 39389599

Group type: EXPERIMENTAL
Intervention: Patient-derived organoids (PDOs) generated from HNSCC samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood and biological samples (plasma and saliva) collected during treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-culture experiments with PDOs
Number of subjects: 0
Study: 39389623

Group type: EXPERIMENTAL
Intervention: Very preterm born children (<28 and 28-31 weeks gestational age)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Fullterm born siblings
Number of subjects: 442

Group type: COMPARATOR
Intervention: Healthy children from the same time period (secondary analysis)
Number of subjects: 442
Study: 39390132

Group type: EXPERIMENTAL
Intervention: 10 mg bevacizumab-800CW
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 25 mg bevacizumab-800CW
Number of subjects: 18
Study: 39390228

Group type: EXPERIMENTAL
Intervention: Newly restored implant (PICF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Contralateral tooth (GCF)
Number of subjects: 10
Study: 39390276

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum KABP042 + Pediococcus pentosaceus KABP041 (BL + PP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Limosilactobacillus reuteri DSM17938 (LR)
Number of subjects: 112
Study: 39390362

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise program (16-week, 2-3 sessions/week, 60 min/session)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Wait-list control group (maintained usual activity, received monthly health education talk)
Number of subjects: 56
Study: 39390398

Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA booster vaccine
Number of subjects: 0
Study: 39390466

Group type: EXPERIMENTAL
Intervention: Patient Determined Disease Steps (PDDS) scale
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Six-minute walk (6 MW)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Walking Scale-12 (MSWS-12)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Modified Fatigue Impact Scale (MFIS)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Scale-29 (MSIS-29)
Number of subjects: 374
Study: 39390476

Group type: EXPERIMENTAL
Intervention: Student citizens' assembly
Number of subjects: 30
Study: 39390508

Group type: EXPERIMENTAL
Intervention: Salivary DPP-4
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Serum DPP-4
Number of subjects: 45
Study: 39390583

Group type: EXPERIMENTAL
Intervention: MIPD dosing calculator for AUC-based dosing with extra sampling for therapeutic drug monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care dosing and monitoring according to institutional guidelines
Number of subjects: 0
Study: 39390601

Group type: EXPERIMENTAL
Intervention: CPP-FC (Chicago Parent Program adapted for foster and kinship caregivers)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CPP-FC
Number of subjects: 300
Study: 39390616

Group type: EXPERIMENTAL
Intervention: SHR-1707 (2, 6, 20, 40, and 60 mg/kg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SHR-1707 (20 mg/kg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SHR-1707 (2-60 mg/kg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: SHR-1707
Number of subjects: 92
Study: 39390669

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with adults with disabilities and complex health conditions
Number of subjects: 18
Study: 39390760

Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) tablets for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WBM combined with PD-1 blockade in murine models
Number of subjects: 0
Study: 39390990

Group type: EXPERIMENTAL
Intervention: Higher white blood cell (WBC) counts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower white blood cell (WBC) counts
Number of subjects: 0
Study: 39391083

Group type: EXPERIMENTAL
Intervention: Mindfulness-based family psychoeducation (MBFPE)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ordinary family psychoeducation (FPE)
Number of subjects: 65
Study: 39391228

Group type: EXPERIMENTAL
Intervention: Active tDCS followed by ET
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS followed by ET
Number of subjects: 0
Study: 39391324

Group type: EXPERIMENTAL
Intervention: ROTEM-guided blood product transfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care (SOC) based on conventional coagulation test (CCT)
Number of subjects: 40
Study: 39391753

Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Number of subjects: 10
Study: 39391887

Group type: EXPERIMENTAL
Intervention: Alberta Family Integrated Care (FICare)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Alberta FICare
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Higher maternal breastfeeding self-efficacy
Number of subjects: 455
Study: 39391984

Group type: EXPERIMENTAL
Intervention: Increased oxygen extraction fraction (OEF) within DWI lesions
Number of subjects: 134

Group type: COMPARATOR
Intervention: No increased oxygen extraction fraction (OEF) within DWI lesions
Number of subjects: 134
Study: 39392121

Group type: EXPERIMENTAL
Intervention: ALDH1A1/2 activity in bone marrow (BM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactive oxygen species (ROS) levels
Number of subjects: 0
Study: 39392161

Group type: EXPERIMENTAL
Intervention: Protocolized intervention pathway activated by high-risk scores; nurse-implemented uptitration of diuretic for 4 days
Number of subjects: 59
Study: 39392168

Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 0
Study: 39392467

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction exercise (BFRE) at 40% total arterial occlusion pressure, using 30-40% of 1-repetition maximum loads, conducted twice weekly for two weeks
Number of subjects: 6
Study: 39392470

Group type: EXPERIMENTAL
Intervention: Individuals with SCI
Number of subjects: 25
Study: 39392616

Group type: EXPERIMENTAL
Intervention: Algorithm-based mobile texting platform delivering 4 treatment modules (education and behavioral modification, cognitive behavioral therapy, pelvic floor physical therapy, guided mindfulness practices) and an automated weekly message over 6 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Algorithm-based mobile texting platform
Number of subjects: 52
Study: 39392675

Group type: EXPERIMENTAL
Intervention: Mindful and Self-Compassionate Care (MASC) program, a 6-week online intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Health Education Program
Number of subjects: 80
Study: 39392741

Group type: EXPERIMENTAL
Intervention: Any intervention letter
Number of subjects: 299881

Group type: EXPERIMENTAL
Intervention: Repeated letter sent 10 days after the initial letter
Number of subjects: 299881

Group type: EXPERIMENTAL
Intervention: Letter emphasizing potential cardiovascular benefits of vaccination
Number of subjects: 299881

Group type: COMPARATOR
Intervention: Usual care (no letter)
Number of subjects: 299881
Study: 39392862

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using KABC-II
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: School achievement test score
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Executive function assessment
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Growth and physical function outcomes
Number of subjects: 1366
Study: 39393026

Group type: EXPERIMENTAL
Intervention: Adjuvant Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39393045

Group type: EXPERIMENTAL
Intervention: IV natalizumab Q6W dosing
Number of subjects: 486

Group type: COMPARATOR
Intervention: IV natalizumab Q4W dosing
Number of subjects: 486

Group type: COMPARATOR
Intervention: Comparison of Q6W vs Q4W dosing
Number of subjects: 486
Study: 39393054

Group type: EXPERIMENTAL
Intervention: Apsou mobile serious game for automated detection of NDs
Number of subjects: 229
Study: 39393084

Group type: EXPERIMENTAL
Intervention: 60-mg admilparant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30-mg admilparant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39393172

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 72
Study: 39393177

Group type: EXPERIMENTAL
Intervention: 3D-enhanced training models
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard 3D LapPass training models
Number of subjects: 65
Study: 39393494

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) breakfast
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normal-Protein (NP) breakfast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Breakfast-skipping (BS) group
Number of subjects: 30
Study: 39393498

Group type: EXPERIMENTAL
Intervention: Eating in the absence of hunger (EAH)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sweet food EAH
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Savory food EAH
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High MVPA and low sedentary time
Number of subjects: 72
Study: 39393528

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) with sevoflurane-dexmedetomidine, continuous infusion of lidocaine and ketamine, and magnesium sulfate during induction
Number of subjects: 155

Group type: COMPARATOR
Intervention: Opioid-sparing anesthesia (OSA) with sevoflurane-sufentanil boluses and continuous infusion of lidocaine
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: OFA group
Number of subjects: 155

Group type: COMPARATOR
Intervention: OSA group
Number of subjects: 155
Study: 39393530

Group type: EXPERIMENTAL
Intervention: Endoscopic Nipple Sparing Mastectomy (E-NSM)
Number of subjects: 10
Study: 39393777

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (±bevacizumab)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (±bevacizumab)
Number of subjects: 617
Study: 39393844

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) - 20 million cells via intradiscal injection
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham placebo injection
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Allogeneic BM-MSCs
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 114
Study: 39393926

Group type: EXPERIMENTAL
Intervention: Allied healthcare
Number of subjects: 1333
Study: 39394025

Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105

Group type: COMPARATOR
Intervention: ShotBlocker®
Number of subjects: 105
Study: 39394112

Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Peripheral Oxygen Saturation (SpO2)
Number of subjects: 102
Study: 39394126

Group type: EXPERIMENTAL
Intervention: Children with spastic CP (MAL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Children with spastic CP (LAL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 28
Study: 39394132

Group type: EXPERIMENTAL
Intervention: ScreenMen web-based app
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: QR codes on buntings
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Postcards
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Identify and prepare champions strategy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mandate change strategy
Number of subjects: 47
Study: 39394158

Group type: EXPERIMENTAL
Intervention: CR + BWLT (12 weekly, group-based virtual sessions, followed by 12 weeks of follow-up support)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CR-only (supervised exercise and risk factor self-management for 12 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CR + BWLT
Number of subjects: 120

Group type: COMPARATOR
Intervention: CR-only
Number of subjects: 120
Study: 39394167

Group type: EXPERIMENTAL
Intervention: Health dialogue intervention (systematic screening followed by an individually oriented lifestyle-focused health dialogue)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Opportunistic screening (screening for a smaller set of risk factors during an appointment for other reasons)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Health dialogue intervention
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Health dialogue intervention and opportunistic screening
Number of subjects: 3000
Study: 39394177

Group type: EXPERIMENTAL
Intervention: Radiotherapy and temozolomide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Omics features
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 34
Study: 39394183

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 39394576

Group type: EXPERIMENTAL
Intervention: Safe-falling training program
Number of subjects: 8
Study: 39394603

Group type: EXPERIMENTAL
Intervention: Dynamic lighting condition with increased brightness in the morning
Number of subjects: 70

Group type: COMPARATOR
Intervention: Static lighting condition with fixed brightness and color
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dynamic lighting condition with increased morning brightness after cross-over
Number of subjects: 70
Study: 39394763

Group type: EXPERIMENTAL
Intervention: Leukocyte-rich PRP (LR-PRP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Leukocyte-poor PRP (LP-PRP)
Number of subjects: 132
Study: 39394845

Group type: EXPERIMENTAL
Intervention: Intraepidermal nerve fiber density (IENFD)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Confocal corneal microscopy (CCM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument questionnaire (MNSIq)
Number of subjects: 140
Study: 39395074

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating quantitative flow ratio derived pullback pressure gradient (QFR-PPG) and four conventional parameters
Number of subjects: 421